Innoviva Secures Average Price Target of $38.80 from Analysts

Shares of Innoviva, Inc. (NASDAQ: INVA) have garnered an average recommendation of “Moderate Buy” from analysts who follow the company, according to a report from MarketBeat.com. Among the seven analysts covering Innoviva, one has assigned a sell rating, another a hold, while five analysts have issued buy ratings. The consensus twelve-month price target stands at $38.80.

Recent analyst reports have reflected varying sentiments on Innoviva’s stock. On December 29, 2023, Weiss Ratings reaffirmed a “buy (b)” rating for the company’s shares. Meanwhile, Zacks Research downgraded Innoviva from a “strong-buy” to a “hold” rating in a report dated November 6, 2023. The same day, Cantor Fitzgerald raised its price target from $29.00 to $31.00 while maintaining an “overweight” rating. In an earlier note on October 25, 2023, Wall Street Zen upgraded Innoviva from a “buy” to a “strong-buy” rating. Furthermore, HC Wainwright increased their price target from $45.00 to $46.00, affirming a “buy” rating on December 16, 2023.

Innoviva’s Financial Performance

Innoviva last reported its earnings on November 5, 2023, revealing a robust performance. The biotechnology firm reported earnings per share (EPS) of $1.08 for the quarter, significantly surpassing the consensus estimate of $0.46 by $0.62. The company also posted a net margin of 32.78% and a return on equity of 28.17%. Revenue for the quarter reached $107.80 million, exceeding the anticipated $91.31 million. Analysts predict that Innoviva will achieve an EPS of 0.33 for the current fiscal year.

Institutional Investment Trends

Recent movements by institutional investors suggest growing confidence in Innoviva. Marshall Wace LLP significantly increased its stake by 870.3% during the second quarter, acquiring 1,332,966 shares valued at approximately $26.78 million. Vanguard Group Inc. also raised its holdings by 11.6% in the fourth quarter, now owning 7,917,103 shares worth about $158.26 million.

Additionally, Arrowstreet Capital Limited Partnership boosted its investment by 85.3% during the same period, resulting in ownership of 1,708,482 shares valued at $34.32 million. Boston Partners increased its stake by 63.6% in the third quarter, acquiring 1,431,601 shares worth approximately $26.13 million. Lastly, Royce & Associates LP raised its holdings by 641.2%, now owning 505,906 shares valued at $9.23 million.

Overall, institutional investors own 99.12% of Innoviva’s stock, indicating strong backing from the investment community.

About Innoviva, Inc.: Headquartered in San Francisco, California, Innoviva is a royalty-focused life sciences company that specializes in acquiring, managing, and monetizing royalty and license interests in biopharmaceutical products. The company primarily focuses on inhaled respiratory therapies, with its portfolio anchored by royalties from therapies developed by its former affiliate, now marketed by GlaxoSmithKline. Innoviva was established through a spin-out transaction in 2014 to create a specialized investment vehicle.

As the market continues to evolve, Innoviva remains in a pivotal position, reflecting the confidence of analysts and investors alike.